West China Hospital for International Patients: Access, Services and Travel Planning
- MedBridgeNZ
- 1 day ago
- 12 min read
West China Hospital is a high-volume tertiary referral hospital in Chengdu, China, with specialized departments that may be relevant to selected international patients [1]. Access is not automatic: the receiving department must independently review the patient’s medical records, determine whether further consultation or assessment is appropriate, confirm current capacity, and provide case-specific next-step information. MedBridgeNZ provides non-clinical coordination to assist patients in navigating this system.
Quick Answer
For international patients exploring West China Hospital, the administrative pathway generally involves:
Record Preparation: Depending on the receiving department, medical records may require professional Chinese translation, a bilingual clinical summary, or reorganization into the format requested by the hospital.
Hospital Submission: Records may be submitted through the hospital’s published international healthcare contact pathway or another department-specific process, where available [6].
Next-Step Confirmation: If the hospital is willing to proceed, it may request additional information or provide instructions regarding consultation arrangements, scheduling, estimated costs, or deposits. These details may be confirmed at different stages.
Logistical Support: MedBridgeNZ assists with non-clinical communication, travel planning, accommodation, and hospital navigation after the relevant arrangements have been confirmed.
Request an Initial Medical Records Readiness Check
Submit your initial inquiry and available medical records. Our Patient Care Team can review the submitted files for obvious administrative gaps and explain the possible hospital-submission process. This is not a medical review and does not guarantee hospital acceptance.
West China Hospital at a Glance
According to West China Hospital’s current institutional overview, the hospital recorded approximately 7.64 million outpatient and emergency visits, discharged approximately 280,000 inpatients, and performed more than 220,000 surgical procedures in 2025. The hospital-wide average length of stay was 6.74 days [1].
Important Limitation: These are hospital-wide operational figures. They do not predict appointment waiting times, admission decisions, treatment duration, or clinical outcomes for an individual international patient.
Fudan Rankings: In the 2021 China’s Hospital Rankings, West China Hospital ranked second overall for the 13th consecutive year [2].
STEM Rankings: In the 2023 China Hospital Science and Technology Evaluation Metrics ranking, released in July 2024, West China Hospital ranked first overall for the 11th consecutive year [3].
What Services Are Currently Operational?
The following services form part of the hospital’s established infrastructure, although individual access remains subject to departmental review, current capacity, and clinical eligibility.
International Healthcare Pathway: West China Hospital publishes dedicated appointment and support information for international patients [6]. Available appointment routes, inpatient arrangements, room types, language support, and department access should be confirmed at the time of inquiry.
Day Surgery Services: West China Hospital operates an established multi-campus day-surgery program. In January 2025, the former Huaxiba day-surgery ward was relocated to the Jinjiang Campus, which formally opened the following month. The Jinjiang and Wenjiang campuses now provide complementary day-surgery services [4].
Day Surgery Capacity: The Jinjiang Campus day-surgery ward opened with 40 beds, and a hospital update published in February 2025 reported an annual procedural volume exceeding 12,000 [4]. At the institution-wide level, West China Hospital stated that its day-surgery program had covered more than 500 procedure types by 2024 [5].
Eligibility Notice: These figures describe the hospital-wide program. They do not mean that every procedure is available to international patients or appropriate for day surgery. Eligibility is determined by the treating department.
Minimally Invasive and Robotic Surgery: West China Hospital reports experience with minimally invasive and robotic surgical platforms, including the Da Vinci Xi, in selected specialties [7]. The current availability and appropriateness of a particular platform must be determined by the relevant clinical team after reviewing the individual case.
What Requires Case-Specific Confirmation?
Not all services are uniformly applicable. The following elements must be confirmed on a case-by-case basis before travel:
Treatment and Equipment Availability: Whether a specific therapy, clinical trial, robotic platform, or imaging procedure is currently available.
International Patient Eligibility: Whether the exact department or facility accepts international patients for the proposed pathway.
Appointments and Capacity: Exact scheduling dates for consultations, imaging, procedures, or surgery.
International Insurance and Direct Billing: Whether the receiving entity accepts the patient’s insurer, guarantee letter, or proposed direct-billing arrangement.
Hospital Deposits and Total Costs: Whether an advance deposit is required and which services are included or excluded.
Important: Confirm the Exact Hospital Entity
“West China” may refer to different hospitals, departments, campuses, and affiliated institutions. Services available at West China Hospital in Chengdu, its International Medical Center, West China Lecheng Hospital in Hainan, the Jinjiang Campus, the Wenjiang Campus, and other affiliated facilities may differ in relation to international patient access, insurance billing, clinical trials, deposits, and payment procedures.
Patients should confirm the full legal and institutional name of the receiving facility before relying on information about treatment availability, insurance, costs, or appointment procedures.
Investigational Therapies and Clinical Research
Patients exploring additional institutional or research pathways often inquire about cellular immunotherapies. It is critical to distinguish between commercially available treatments and early-phase research.
What the Early-Phase EpCAM CAR-T Study Reported
Researchers from Sichuan University, West China Hospital, and collaborating institutions reported an investigational CAR-T approach incorporating Dectin-1 co-stimulation and designed to target the EpCAM antigen in epithelial-derived solid tumors [8].
Study Design: Phase 1, multicenter, open-label clinical study [8,9].
Participants: Twelve participants with advanced EpCAM-positive epithelial tumors who met the study’s protocol-defined eligibility criteria [8,9].
Primary Purpose: To evaluate early safety and treatment-related adverse events [8,9].
Secondary or Exploratory Purpose: To observe preliminary antitumor activity [8].
Reported Observations: Partial response and stable disease were reported in some participants [8].
Important Limitations: This was a small, non-randomized phase 1 study. Its safety and preliminary activity findings should not be generalized beyond the protocol-defined cohort and do not establish routine efficacy, comparative benefit, or suitability for an individual patient [8].
Current Access: The trial registry does not establish current recruitment or routine treatment availability. Current recruitment, treatment access, and eligibility for international patients must be confirmed directly with the hospital or research team [9].
West China Proton and Heavy-Ion Facility
Project information published in August 2023 stated that phase one of the West China International Oncology Treatment Center was expected to be completed and enter trial operation by the end of that year [11].
In November 2024, China’s National Nuclear Safety Administration reported that the first proton therapy equipment was ready to be transported to the center for installation and commissioning [10].
These sources do not confirm the facility’s current operational or patient-intake status. Formal opening, routine treatment availability, international patient access, and pricing should be verified directly with the institution [10,11].
Publicly Documented Facility Status
Planned trial operation: Anticipated by the end of 2023 in project information published in August 2023 [11].
Equipment installation preparations: Reported in November 2024 [10].
What Medical Records May Be Needed?
Depending on the condition and receiving department, requested records may include:
A recent clinical summary and prior treatment history;
Relevant operative, discharge, and treatment reports;
Imaging reports and original DICOM files, such as CT, MRI, or PET-CT where relevant;
Recent laboratory results relevant to the condition;
Pathology reports and molecular testing, where applicable;
Physical pathology slides or blocks, only when specifically requested.
Exact submission requirements must be confirmed with the receiving department or research team.
Record Sharing and Authorization: Medical records should be submitted only with the patient’s authorization and through an agreed transfer method. Patients should confirm which institution or department will receive the files before sharing sensitive health information.
How Hospital Review Usually Works
Upon receiving a medical dossier, the case may first be reviewed by an appropriate clinician, department, or international healthcare team. A multidisciplinary review, or MDT, may be arranged where clinically indicated and available.
The hospital may indicate whether a consultation or further assessment is appropriate and may request additional records, tests, or an in-person evaluation. Scheduling and financial information may be provided later, depending on the pathway.
Representative Administrative Pathway
The following pathway is illustrative. It does not imply any guaranteed outcome or acceptance.
Clinical Context: A patient exploring options after prior treatments compiles their local medical records.
Administrative Formatting: MedBridgeNZ assists with professional medical translation using appropriate Chinese medical terminology and organizes the files in the format requested by the receiving institution or department.
Submission Routing: With the patient’s authorization, the formatted dossier is routed to a potentially relevant department for hospital-led review.
Institutional Feedback: The hospital may indicate whether further review or consultation is appropriate, request additional information, and provide next-step instructions. Scheduling and financial information may be confirmed separately.
Logistical Coordination: If the pathway proceeds, MedBridgeNZ assists with ground logistics, non-clinical communication, and accommodation arrangements.
Costs, Deposits, and Insurance
China’s national Volume-Based Procurement program has reduced the procurement prices of selected high-value medical consumables, including certain coronary stents and artificial joints [12,13].
These national procurement reductions do not determine the total bill for an international patient. Total charges may also include professional services, investigations, surgery, anesthesia, inpatient care, non-covered products, international-service arrangements, and complication management.
Advance Deposits: An advance deposit may be required depending on the hospital entity, department, proposed treatment pathway, and payment arrangement. Before making payment, patients should request written confirmation of the legal payee, included and excluded services, payment schedule, additional-deposit conditions, refund terms, and whether any third-party provider will charge separately.
Insurance: International insurance acceptance and direct-billing arrangements vary by hospital entity, department, insurer, policy, and individual case. Patients must obtain written confirmation from both the exact receiving hospital entity and their insurer before relying on coverage.
Visa and Entry Planning
240-Hour Visa-Free Transit
Eligible passport holders may qualify for the 240-hour visa-free transit policy when all nationality, itinerary, port, permitted-stay-area, and onward-travel requirements are met [14].
The policy should not be presented or relied upon as a medical-admission pathway. Travelers considering a hospital visit during a qualifying transit should verify the current list of eligible nationalities, itinerary requirements, permitted stay areas, and permitted activities with the relevant immigration authority before booking.
S2 or Other Lawful Entry Pathways
Depending on nationality, itinerary, expected length of stay, and supporting documents, an S2 visa for short-term private affairs or another lawful entry pathway may be relevant [15].
Final visa category, documentation requirements, processing time, and approval are determined by the relevant Chinese embassy, consulate, visa service center, or immigration authority [15].
Clinical and Travel Risks
Patients with unstable medical conditions, active serious infections, an immediate need for intensive care, or concerns about fitness to fly may not be suitable for elective international medical travel.
Travel safety must be assessed by the patient’s current clinicians, the receiving hospital, and, where applicable, the airline’s medical-clearance team.
What MedBridgeNZ Does—and Does Not Do
We may: With the patient’s authorization, organize and route records to a potentially relevant department, coordinate administrative submission based on the stated diagnosis, facilitate hospital communication, assist with professional translation, communicate hospital-provided feedback, and arrange non-clinical logistics.
We do not: Diagnose conditions, recommend treatments, determine clinical eligibility, or provide medical advice. The hospital and its licensed clinicians independently determine whether a department is appropriate and whether the patient is clinically eligible for any consultation, procedure, treatment, or research program.
For a full overview of our administrative coordination, medical-record preparation, translation, travel planning, and hospital-navigation support, see our medical concierge services in China.
What Is Confirmed—and What Requires Hospital Verification?
Topic | What Can Be Confirmed Publicly | What Requires Case-Specific Confirmation |
Hospital existence and departments | Public institutional information, hospital-wide scale, and published international healthcare pathways [1,6]. | Current appointment capacity and acceptance of a specific case. |
CAR-T research | Published phase 1 findings and protocol information [8,9]. | Current recruitment, treatment access, and eligibility [9]. |
Proton/heavy-ion center | Anticipated trial-operation timeline and subsequent equipment installation preparations [10,11]. | Current operational status, formal opening, routine patient intake, and international access [10,11]. |
Insurance | A hospital-wide international direct-billing policy should not be assumed from arrangements associated with another department or affiliated institution. | Whether the exact receiving entity accepts the patient’s insurer, guarantee letter, or direct-billing arrangement. |
Costs | General billing components and national procurement policies; these are not hospital quotations [12,13]. | A written, patient-specific estimate, deposit requirement, legal payee, exclusions, and refund terms. |
Frequently Asked Questions
1. Can international patients request a review from West China Hospital?
International patients may request a hospital review or ask whether their records can be submitted through the hospital’s international healthcare or department-specific pathways [6]. Submission does not guarantee consultation, treatment, or admission.
2. What records may be requested before hospital submission?
Depending on the condition, the hospital may request a clinical summary, prior treatment and operative reports, relevant DICOM imaging, recent laboratory results, and, where applicable, pathology or molecular testing.
Exact requirements must be confirmed with the receiving department.
3. Does submitting records guarantee consultation, treatment, or admission?
No. Clinical acceptance, treatment recommendations, and admission are entirely subject to the independent judgment of the hospital’s medical team after reviewing the files.
4. Is the EpCAM-targeted CAR-T study routinely available to international patients?
The study discussed in this article should not be interpreted as evidence of routine commercial availability. Current recruitment, treatment access, and eligibility for international patients cannot be assumed and must be confirmed directly with the hospital or research team [8,9].
5. Is the West China proton and heavy-ion facility accepting routine patients?
Publicly available project information described an anticipated trial-operation timeline and subsequent equipment installation preparations [10,11].
However, these sources do not confirm the facility’s current operational status, formal routine patient intake, international patient access, or treatment pricing. Current status should be verified directly with the institution [10,11].
6. How are costs, deposits, and insurance confirmed?
Payment and deposit requirements vary substantially. Patients should request a written, case-specific estimate that identifies the legal payee, included and excluded services, payment schedule, deposit requirements, and refund terms.
Insurance acceptance must be confirmed in writing by both the exact receiving hospital entity and the insurer before travel.
7. What should travelers know about the 240-hour visa-free transit policy?
This is an immigration transit policy subject to strict itinerary and nationality requirements [14]. It does not guarantee entry and should not be relied upon as a medical-admission pathway.
Request an Initial Medical Records Readiness Check
Submit your initial inquiry and available medical records. Our Patient Care Team can review the submitted files for obvious administrative gaps and explain the possible hospital-submission process. This is not a medical review and does not guarantee hospital acceptance.
Disclaimer: MedBridgeNZ acts strictly as an international medical concierge and logistics coordinator. We do not provide direct medical treatment, diagnosis, or clinical advice. This content is for informational purposes only and does not constitute medical guidance. Always consult your primary physician or treating oncologist before pursuing cross-border treatment options or undertaking international travel.
References
[1] West China Hospital, Sichuan University. “Overview.” Accessed July 22, 2026.https://www.wchscu.cn/details/50453.html
[2] West China Hospital, Sichuan University. “WCH Ranks Second in the China’s Hospital Rankings for 13 Consecutive Years.”https://www.wchscu.cn/details/71747.html
[3] West China Hospital, Sichuan University. “四川大学华西医院超声医学专业位列2023年度中国医院科技量值（STEM）超声医学专业全国第一” [West China Hospital Ranked First in the 2023 China Hospital Science and Technology Evaluation Metrics]. July 23, 2024.https://www.wchscu.cn/public/department/ultrasound/dynamics/81414.html
[4] West China Hospital, Sichuan University. “四川大学华西医院锦江院区日间手术中心全面启用，开启高效医疗服务新篇章” [West China Hospital’s Jinjiang Campus Day Surgery Center Fully Opens]. February 20, 2025.https://www.wchscu.cn/public/department/DaySurgeryCenter/dynamics/84619.html
[5] West China Hospital, Sichuan University. “日间手术中心” [Day Surgery Center]. Accessed July 22, 2026.https://www.wchscu.cn/department_rjfwzx.html
[6] West China Hospital, Sichuan University. “International Healthcare.” Accessed July 22, 2026.https://www.wchscu.cn/en/interna_heal.html
[7] West China Hospital, Sichuan University. “我院开展四川省首例Xi机器人手术” [West China Hospital Performs Sichuan’s First Xi Robotic Surgery]. June 29, 2020.https://www.wchscu.cn/technology/52185.html
[8] Li, Dan, Xianling Guo, Kun Yang, et al. “EpCAM-Targeting CAR-T Cell Immunotherapy Is Safe and Efficacious for Epithelial Tumors.” Science Advances. 2023;9(48):eadg9721.DOI: https://doi.org/10.1126/sciadv.adg9721Open-access full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC10691766/
[9] ClinicalTrials.gov. “EpCAM CAR-T for Treatment of Advanced Solid Tumors.” ClinicalTrials.gov Identifier: NCT02915445. Last update posted November 22, 2023.https://clinicaltrials.gov/study/NCT02915445
[10] National Nuclear Safety Administration of China. “国内首座商用多室质子治疗设备生产基地首台设备下线” [First Equipment Rolls Off China’s First Commercial Multi-Room Proton Therapy Equipment Production Line]. November 8, 2024.https://nnsa.mee.gov.cn/ywdt/hyzx/202411/t20241108_1093760.html
[11] National Business Daily. “华西国际肿瘤治疗中心（重离子质子）项目1期预计年底试运行 成都天府国际生物城‘全面国际化医疗’建设再提速” [Phase One of the West China International Oncology Treatment Center Expected to Enter Trial Operation by Year-End]. August 30, 2023.https://www.nbd.com.cn/rss/toutiao/articles/2995037.html
[12] National Healthcare Security Administration of China. “国家医疗保障局关于国家组织冠脉支架集中带量采购和使用配套措施的意见” [Supporting Measures for the National Volume-Based Procurement and Use of Coronary Stents]. December 17, 2020.https://www.nhsa.gov.cn/art/2020/12/17/art_104_6512.html
[13] National Healthcare Security Administration of China and National Health Commission of China. “国家医保局办公室 国家卫生健康委办公厅关于国家组织高值医用耗材（人工关节）集中带量采购和使用配套措施的意见” [Supporting Measures for National Volume-Based Procurement and Use of Artificial Joints]. March 31, 2022.https://www.nhsa.gov.cn/art/2022/3/31/art_37_8042.html
[14] National Immigration Administration of China. “Visa-Free Transit Policies.” July 4, 2025.https://en.nia.gov.cn/n147418/n147463/c183412/content.html
[15] Department of Consular Affairs, Ministry of Foreign Affairs of the People’s Republic of China. “私人事务签证（S1和S2字签证）颁发对象和所需材料是什么？” [Who May Apply for S1 and S2 Private-Affairs Visas and What Documents Are Required?]. May 6, 2026.https://cs.mfa.gov.cn/wgrlh/lhqz/cjwdn_660600/201407/t20140718_961506.shtml
Written by: MedBridgeNZ
Last updated: July 2026
Content methodology: Publicly confirmed institutional information is distinguished from historical data, early-phase research, planned or trial-stage facilities, and case-specific administrative arrangements. Treatment availability, clinical eligibility, and costs must be confirmed directly by the receiving institution.
Independence Notice: MedBridgeNZ is an independent international medical concierge. It is not part of West China Hospital and does not speak or make clinical decisions on the hospital’s behalf. Mention of the hospital does not imply endorsement, agency, guaranteed appointment access, hospital acceptance, or treatment availability.
